Merit Medical SystemsMMSI
MMSI
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
195,569% more call options, than puts
Call options by funds: $93.9M | Put options by funds: $48K
200% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]
41% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 109
22% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 51
2.15% more ownership
Funds ownership: 102.54% [Q3] → 104.69% (+2.15%) [Q4]
1% more funds holding
Funds holding: 373 [Q3] → 376 (+3) [Q4]
0% more capital invested
Capital invested by funds: $5.88B [Q3] → $5.9B (+$25.9M) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$111
6%
upside
Avg. target
$118
12%
upside
High target
$127
21%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Robbie Marcus 53% 1-year accuracy 10 / 19 met price target | 14%upside $120 | Overweight Initiated | 28 Mar 2025 |
Barrington Research Michael Petusky 35% 1-year accuracy 25 / 72 met price target | 6%upside $111 | Outperform Maintained | 26 Feb 2025 |
Canaccord Genuity Jon Young 71% 1-year accuracy 5 / 7 met price target | 21%upside $127 | Buy Maintained | 26 Feb 2025 |
Wells Fargo Larry Biegelsen 36% 1-year accuracy 17 / 47 met price target | 12%upside $117 | Overweight Maintained | 26 Feb 2025 |
Needham Mike Matson 40% 1-year accuracy 50 / 124 met price target | 11%upside $116 | Buy Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 8 articles about MMSI published over the past 30 days
Positive
Zacks Investment Research
6 hours ago
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
Merit Medical's strong product portfolio raises optimism about the stock.
Neutral
GlobeNewsWire
5 days ago
Updated ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD
Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms. Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms.
Positive
Zacks Investment Research
6 days ago
Merit Medical Stock May Rise as WRAPSODY CIE Shows Strong Results
MMSI unveils 12-month efficacy data for WRAPSODY CIE, highlighting its advanced technology in vascular access maintenance and potential to improve patient outcomes.
Neutral
GlobeNewsWire
1 week ago
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)
SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial are scheduled for publication in the April issue of Kidney International . Twelve-month results from the randomized arm of the WAVE trial are scheduled for presentation at the Society of Interventional Radiology's 50th Annual Scientific Meeting in Nashville, TN. The podium presentation is scheduled for March 30, 2025, during the late-breaking trials session.
Neutral
GlobeNewsWire
2 weeks ago
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred Lampropoulos, will visit the Nasdaq MarketSite in Times Square to ring the opening bell on Wednesday, March 19, 2025. The ceremony begins at 9:15 A.M. (EDT) and the bell ringing takes place at 9:30 A.M.
Positive
Seeking Alpha
2 weeks ago
Merit Medical: A Success Story That Keeps Getting Better
Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical's lead management portfolio, enhance Merit's product portfolio and offer longer-term synergies.
Positive
Zacks Investment Research
2 weeks ago
MMSI Announces Commencement of Patient Enrollment in PREEMIE Study
Merit Medical aims to improve care for vulnerable premature infants by evaluating the safety and efficacy of the Bloom Micro Occluder System for treating PDA in the specified patient pool.
Neutral
GlobeNewsWire
3 weeks ago
First Patient Enrolled in Merit Medical's PREEMIE Study
Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants
Neutral
Seeking Alpha
1 month ago
Merit Medical Systems, Inc. (MMSI) Q4 2024 Earnings Call Transcript
Merit Medical Systems, Inc. (MMSI) Q4 2024 Earnings Call Transcript
Neutral
Zacks Investment Research
1 month ago
Compared to Estimates, Merit Medical (MMSI) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Charts implemented using Lightweight Charts™